Focused On-demand Library for Ribonuclease pancreatic

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P07998

UPID:

RNAS1_HUMAN

Alternative names:

HP-RNase; RIB-1; RNase UpI-1; Ribonuclease 1; Ribonuclease A

Alternative UPACC:

P07998; B2R589; D3DS06; Q16830; Q16869; Q1KHR2; Q6ICS5; Q9UCB4; Q9UCB5

Background:

Ribonuclease pancreatic, known by alternative names such as HP-RNase and Ribonuclease A, plays a crucial role in RNA metabolism. It catalyzes the cleavage of RNA on the 3' side of pyrimidine nucleotides, impacting both single-stranded and double-stranded RNA. This enzyme's activity is essential for the processing and maturation of RNA, a fundamental process in cellular biology.

Therapeutic significance:

Understanding the role of Ribonuclease pancreatic could open doors to potential therapeutic strategies. Its ability to target RNA molecules offers a promising avenue for the development of novel treatments, particularly in diseases where RNA processing is compromised.